ATE202487T1 - Mono- oder polyfunktionelle konjugate von polylysine - Google Patents

Mono- oder polyfunktionelle konjugate von polylysine

Info

Publication number
ATE202487T1
ATE202487T1 AT95940329T AT95940329T ATE202487T1 AT E202487 T1 ATE202487 T1 AT E202487T1 AT 95940329 T AT95940329 T AT 95940329T AT 95940329 T AT95940329 T AT 95940329T AT E202487 T1 ATE202487 T1 AT E202487T1
Authority
AT
Austria
Prior art keywords
pct
polylysine
diseases
mono
sec
Prior art date
Application number
AT95940329T
Other languages
English (en)
Inventor
Michel Geffard
Original Assignee
Michel Geffard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michel Geffard filed Critical Michel Geffard
Application granted granted Critical
Publication of ATE202487T1 publication Critical patent/ATE202487T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyamides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95940329T 1994-11-18 1995-11-17 Mono- oder polyfunktionelle konjugate von polylysine ATE202487T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9413861A FR2727117A1 (fr) 1994-11-18 1994-11-18 Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
PCT/FR1995/001517 WO1996015810A1 (fr) 1994-11-18 1995-11-17 Conjugues monofonctionnels et/ou polyfonctionnels de la polylysine

Publications (1)

Publication Number Publication Date
ATE202487T1 true ATE202487T1 (de) 2001-07-15

Family

ID=9468953

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940329T ATE202487T1 (de) 1994-11-18 1995-11-17 Mono- oder polyfunktionelle konjugate von polylysine

Country Status (14)

Country Link
US (1) US6114388A (de)
EP (1) EP0792167B1 (de)
JP (1) JP4128618B2 (de)
AT (1) ATE202487T1 (de)
AU (1) AU694825B2 (de)
CA (1) CA2205557C (de)
DE (1) DE69521521T2 (de)
DK (1) DK0792167T3 (de)
ES (1) ES2161915T3 (de)
FR (1) FR2727117A1 (de)
GR (1) GR3036710T3 (de)
NZ (1) NZ297040A (de)
PT (1) PT792167E (de)
WO (1) WO1996015810A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO104396A0 (en) 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
DE69835201T2 (de) 1997-04-18 2007-06-14 Novartis Ag Neoglycoproteine
FR2763853B1 (fr) * 1997-05-28 2000-01-07 Oreal Association d'un retinoide avec un polymere polyamine
DE19732139C2 (de) * 1997-07-25 2002-10-10 Max Planck Gesellschaft Mesomorphe Komplexe aus Vitamin A-Säure und kationischen Polyelektrolyten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
FR2773808B1 (fr) * 1998-01-20 2000-05-05 Sagebo Composes susceptibles de pieger les ions metalliques, leur procede d'obtention et leur utilisation
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6686446B2 (en) * 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
GB9811059D0 (en) * 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
KR100645980B1 (ko) 1998-07-30 2006-11-14 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 항암 활성을 갖는 약제의 제조에서 l-카르니틴 및 그의알카노일 유도체의 용도
WO2000068252A1 (en) * 1999-05-10 2000-11-16 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
ES2545736T3 (es) * 2002-08-08 2015-09-15 Baylor College Of Medicine Aislamiento e identificación de células T
WO2004020673A1 (en) * 2002-08-28 2004-03-11 Millipore Corporation Compositions of solution for sequencing reaction clean-up
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
DK2030622T3 (da) * 2005-03-24 2011-05-02 Univ Emory Doseringsangivelse af progesteron i behandlingen af en traumatisk hjerneskade
FR2886153B1 (fr) * 2005-05-27 2009-04-10 Gemac Sa Composition destinee au traitement de la sclerose en plaques
DK2016414T3 (en) * 2006-05-05 2015-12-07 Opexa Therapeutics T-cell vaccine
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
AU2007336692B2 (en) 2006-12-22 2013-12-12 Croma-Pharma Gesellschaft M.B.H. Use of polymers
FR2913335B1 (fr) 2007-03-06 2009-06-05 Michel Geffard Utilisation de conjugues d'acides gras et de poly-l-lysine pour lutter contre des microorganismes pathogenes.
EP2085082A1 (de) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Behandlung kognitiven Abbaus
BR112013026082A2 (pt) * 2011-04-12 2019-09-24 Nestec Sa composições nutricionais incluindo ácidos graxos de cadeia ramificada para melhorar função de barreira intestinal
DK3116887T3 (da) 2014-03-13 2021-04-26 Univ Basel Carbonhydratligander, der binder til igm-antistoffer mod myelin-associeret glykoprotein
FR3030524B1 (fr) 2014-12-17 2017-01-20 Hydro-Fill Utilisation de pll pour ameliorer la stabilite de molecules en solution
CN108026134A (zh) 2015-09-16 2018-05-11 巴塞尔大学 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体
FR3048616B1 (fr) 2016-03-14 2018-04-06 Polyneuros Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique
FR3122571B1 (fr) * 2021-05-10 2023-05-12 Hydro Fill Tech Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles
FR3122573B1 (fr) * 2021-05-10 2024-03-29 Hydro Fill Tech Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55500053A (de) * 1978-01-16 1980-01-31
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
GB9004538D0 (en) * 1990-02-28 1990-04-25 Offord Robin E Chemical compounds
GEP20033082B (en) * 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
AU4534593A (en) * 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
FR2705234B1 (fr) * 1993-05-19 1995-08-04 Geffard Michel Utilisation de molécules reconnues par des autoanticorps de sérums humains pour le diagnostic ou le traitement du SIDA.

Also Published As

Publication number Publication date
AU4181196A (en) 1996-06-17
JPH10511643A (ja) 1998-11-10
AU694825B2 (en) 1998-07-30
FR2727117A1 (fr) 1996-05-24
ES2161915T3 (es) 2001-12-16
EP0792167B1 (de) 2001-06-27
PT792167E (pt) 2001-12-28
WO1996015810A1 (fr) 1996-05-30
FR2727117B1 (de) 1997-02-21
DK0792167T3 (da) 2001-10-29
NZ297040A (en) 1999-05-28
DE69521521T2 (de) 2002-04-25
DE69521521D1 (de) 2001-08-02
US6114388A (en) 2000-09-05
EP0792167A1 (de) 1997-09-03
GR3036710T3 (en) 2001-12-31
JP4128618B2 (ja) 2008-07-30
CA2205557C (en) 2008-07-15
CA2205557A1 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
ATE202487T1 (de) Mono- oder polyfunktionelle konjugate von polylysine
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
PL328858A1 (en) Immunogenous peptides
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
MY132529A (en) Paroxetine hydrochloride anhydrate
AU2291097A (en) Novel phenanthridines substituted in the 6 position
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
HK1023770A1 (en) Chalcones having antiproliferative activity.
ATE238990T1 (de) Pyridylthioverbindungen zur bekämpfung von helicobacter-bakterien
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
DE69734237D1 (de) Drogen untersuchungssystem
DE69726602D1 (en) Hepatitis b inhibitoren
TR199800850T2 (xx) Kan� d�zenleyici bile�imler.
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee